Equities Analysts Issue Forecasts for CORT FY2026 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at HC Wainwright dropped their FY2026 EPS estimates for Corcept Therapeutics in a research note issued to investors on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of $2.05 for the year, down from their previous estimate of $2.15. HC Wainwright currently has a “Buy” rating and a $165.00 target price on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.83 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.98 EPS, Q2 2027 earnings at $0.80 EPS, Q3 2027 earnings at $0.94 EPS, Q4 2027 earnings at $1.05 EPS, FY2027 earnings at $3.39 EPS, FY2028 earnings at $6.76 EPS, FY2029 earnings at $9.58 EPS and FY2030 earnings at $12.92 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.17. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The firm had revenue of $340.47 million for the quarter, compared to the consensus estimate of $339.12 million. During the same period in the prior year, the firm earned $0.16 EPS. The firm’s revenue for the quarter was up 64.0% on a year-over-year basis.

CORT has been the topic of a number of other research reports. Truist Financial initiated coverage on Corcept Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price objective on the stock. Piper Sandler reiterated an “overweight” rating and issued a $173.00 target price (up from $165.00) on shares of Corcept Therapeutics in a report on Wednesday. Weiss Ratings raised Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday. Zacks Research downgraded Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. Finally, Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $139.50.

Corcept Therapeutics Stock Down 9.6%

NASDAQ:CORT opened at $71.63 on Friday. The company has a fifty day simple moving average of $108.46 and a two-hundred day simple moving average of $75.47. The company has a market cap of $7.84 billion, a price-to-earnings ratio of 56.40 and a beta of 0.54. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $126.38.

Institutional Investors Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CORT. New Mexico Educational Retirement Board purchased a new position in shares of Corcept Therapeutics during the third quarter worth about $2,305,000. Ritholtz Wealth Management purchased a new stake in Corcept Therapeutics during the 3rd quarter valued at approximately $213,000. Illinois Municipal Retirement Fund purchased a new stake in Corcept Therapeutics during the 3rd quarter valued at approximately $3,040,000. New York Life Investment Management LLC acquired a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $294,000. Finally, AlphaCore Capital LLC acquired a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $390,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Activity

In related news, Director James N. Wilson sold 10,000 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $114.81, for a total value of $1,148,100.00. Following the transaction, the director owned 1,054,543 shares of the company’s stock, valued at $121,072,081.83. This represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Sean Maduck sold 13,159 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $82.25, for a total value of $1,082,327.75. Following the completion of the sale, the insider owned 9,938 shares in the company, valued at approximately $817,400.50. This represents a 56.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 382,536 shares of company stock valued at $43,406,554 over the last quarter. Company insiders own 20.70% of the company’s stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept reported Q3 earnings of $1.01 per share, above the $0.84 consensus, and revenue of $340.5 million, up 64% year over year and slightly ahead of expectations. Higher Korlym sales and Lifyorli uptake contributed to growth. Article: CORT’s Q3 earnings beat
• Neutral Sentiment: HC Wainwright continues to rate the stock Buy with a $165 target, although it lowered several forecasts. Its longer-term estimates still project earnings growth, including $6.76 per share in 2028 and $12.92 in 2030.
• Negative Sentiment: HC Wainwright cut estimates for Q4 2026 EPS to $0.98 from $1.31 and FY2026 EPS to $2.05 from $2.15. It also reduced its Q2–Q4 2027 quarterly forecasts and lowered FY2027 EPS to $3.39 from $3.95, adding to concerns about the company’s near-term earnings outlook.
• Negative Sentiment: Two insiders sold shares: Roberto Vieira sold 8,333 shares for about $674,000, while Sean Maduck sold more than 25,000 shares across two transactions for roughly $2.05 million. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in company fundamentals. Article: Corcept insider selling
• Negative Sentiment: Shares crossed below their 200-day moving average, a technical signal that may add to selling pressure. Article: CORT crosses below its 200-day moving average

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.